Women's imaging issues seem to be featured everywhere. The momentum has been building over the past decade, propelled by the evident importance of screening mammography, the integration of multimodalities into breast imaging, the success of fibroid embolization, and the emergence of certain distinctions between male and female pathology in lung and cardiac disease.
Women's imaging issues seem to be featured everywhere. The momentum has been building over the past decade, propelled by the evident importance of screening mammography, the integration of multimodalities into breast imaging, the success of fibroid embolization, and the emergence of certain distinctions between male and female pathology in lung and cardiac disease.
Most practices, large and small, have areas dedicated to women's imaging. Many journals and Internet sites have a women's health section or concentration. For years, Diagnostic Imaging has featured special sections and supplements devoted to women's imaging.
There is even a buzz within radiology to recognize women's imaging as its own subspecialty. There are about 30 fellowships for women's imaging, and they've done well in the last several years, according to Dr. Ellen Mendelson, medical director of breast imaging at Northwestern Memorial Hospital in Chicago. But radiology residency programs could do a better job with women's imaging.
"Residencies have to put all the women's imaging curricula into an easy-to-get format, including musculoskeletal for osteoporosis," Mendelson said.
Beyond academia, women's imaging has already been stamped a subspecialty. Women's imaging centers appear everywhere. In these places, patients can have their annual mammogram, a bone mineral test, and gynecological ultrasonography. In our special Women's Health section, we feature one center's journey through renovation and expansion (see page 49). As this is the wave of the future, it wouldn't hurt to learn some tricks from someone else's trials and tribulations.
Mr. Kaiser is news editor of Diagnostic Imaging.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.